Stockreport

Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022

Immunovant, Inc.  (IMVT) 
PDF NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people wit [Read more]